Last updated: February 19, 2026
Nucala (mepolizumab) is a humanized monoclonal antibody targeting interleukin-5 (IL-5). It is indicated for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). The drug's market performance is driven by its efficacy in reducing exacerbations and its expansion into new indications, alongside patent considerations that influence competitive landscapes.
What are Nucala's Approved Indications and Their Market Significance?
Nucala is approved for three distinct indications, each contributing to its market penetration and revenue generation.
-
Severe Eosinophilic Asthma: This was Nucala's initial indication, approved in November 2015 in the United States. The drug targets eosinophilic inflammation, a key driver of severe asthma exacerbations. The global market for severe asthma therapies is substantial, estimated to reach tens of billions of dollars annually. Nucala's ability to reduce exacerbations, hospitalizations, and oral corticosteroid use positions it as a significant treatment option for this patient population. Approximately 5-10% of adult asthma patients have severe eosinophilic asthma, representing a significant addressable market [1].
-
Eosinophilic Granulomatosis with Polyangiitis (EGPA): Approval for EGPA in December 2017 expanded Nucala's utility to a rare autoimmune disease characterized by inflammation of blood vessels. EGPA predominantly affects individuals with eosinophilia. This indication provides Nucala access to a niche but high-need patient group, often managed by specialists. The prevalence of EGPA is estimated to be between 10 and 20 cases per million population [2].
-
Hypereosinophilic Syndrome (HES): Nucala received approval for HES in January 2020. HES is a group of rare disorders characterized by persistent overproduction of eosinophils, which can affect multiple organs. Similar to EGPA, this indication targets a rare disease population, further diversifying Nucala's revenue streams and solidifying its role in treating eosinophil-driven conditions. The prevalence of HES is also considered rare, with estimates varying due to diagnostic challenges.
The approval across these indications is a strategic advantage, allowing GlaxoSmithKline (GSK), the manufacturer, to capture a broader segment of the eosinophil-related disease market.
How has Nucala's Revenue Performance Evolved?
Nucala's financial trajectory demonstrates consistent growth since its launch, fueled by expanding indications and market adoption.
| Year |
Revenue (USD Billions) |
Year-over-Year Growth (%) |
| 2016 |
0.28 |
N/A |
| 2017 |
0.55 |
96.4 |
| 2018 |
0.84 |
52.7 |
| 2019 |
1.10 |
31.0 |
| 2020 |
1.37 |
24.5 |
| 2021 |
1.46 |
6.2 |
| 2022 |
1.55 |
6.2 |
| 2023 |
1.63 |
5.2 |
Source: GlaxoSmithKline (GSK) Annual Reports and Financial Filings [3]
The initial years post-launch showed substantial year-over-year growth. This trend moderated in later years as the drug matured in its primary indication and faced increasing competition. However, revenue growth has remained positive, indicating sustained demand and successful market penetration. The revenue figures highlight Nucala's position as a significant contributor to GSK's respiratory and immunology portfolio. For instance, in 2023, Nucala was GSK's fourth-largest product by sales, contributing approximately 3.4% to the company's total pharmaceutical revenue of £47.7 billion [4].
What is the Competitive Landscape for Nucala?
Nucala operates in a competitive environment with both biologic and non-biologic therapies. Its primary competitors include other IL-5 or IL-5 receptor inhibitors, as well as other biologics targeting different pathways in severe asthma.
-
Tezepelumab (Tezspire): Developed by AstraZeneca and Amgen, Tezspire targets thymic stromal lymphopoietin (TSLP), a key upstream cytokine in the asthma inflammatory cascade. Tezspire was approved in October 2021 for severe asthma and has shown significant efficacy in reducing exacerbations across a broad range of severe asthma patients, regardless of eosinophil levels. This broad applicability presents a significant competitive challenge to Nucala. In 2023, Tezspire generated $770 million in sales globally [5].
-
Dupilumab (Dupixent): Co-developed by Sanofi and Regeneron, Dupixent targets the IL-4 receptor alpha subunit, inhibiting signaling of both IL-4 and IL-13. Dupixent is approved for severe eosinophilic asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Its broad efficacy and multi-indication approval make it a formidable competitor. Dupixent's sales reached $11.9 billion in 2023 [6].
-
Benralizumab (Fasenra): Developed by AstraZeneca, benralizumab is another IL-5 receptor inhibitor approved for severe eosinophilic asthma. It is administered as a subcutaneous injection. In 2023, Fasenra generated $1.27 billion in sales [5].
-
Mepolizumab (Cinqaero/Nucala) Biosimilars: The patent landscape is crucial here. As Nucala's primary patents approach expiration, the threat of biosimilar competition increases. The first biosimilar to Nucala (mepolizumab) was approved in Japan in June 2023, by Meiji Seika Pharma [7]. The entry of biosimilars is anticipated to impact Nucala's market share and pricing power, particularly in regions where biosimilar adoption is robust.
The competitive landscape is dynamic, with ongoing research into novel therapeutic targets and treatment combinations. Nucala's specific targeting of IL-5 and its established efficacy in eosinophilic conditions remain its key differentiators.
What is the Patent Status and Future Patent Cliffs for Nucala?
The patent protection for Nucala is a critical factor influencing its long-term market exclusivity and profitability.
-
Core Compound Patents: The primary patents covering the mepolizumab molecule itself are set to expire. In the United States, key patents are expected to expire around 2027-2030. For example, U.S. Patent No. 7,608,251, covering methods of treating eosinophilic disorders, is listed in the Orange Book with an expiration date of July 2027 [8]. Other formulation and manufacturing process patents may have different expiration timelines.
-
Global Patent Expirations: Patent expiration dates vary by jurisdiction. In Europe, the Supplementary Protection Certificates (SPCs) for Nucala are also set to expire in the coming years, typically around the same timeframe as U.S. expirations, allowing for market exclusivity for a defined period post-patent grant.
-
Biosimilar Entry: The expiration of core compound patents paves the way for biosimilar development and market entry. As noted, the first biosimilar has already been approved in Japan. The U.S. Food and Drug Administration (FDA) has a pathway for biosimilar approval, and generic manufacturers are expected to pursue this once patents lapse. The presence of biosimilars will likely lead to price erosion and a reduction in Nucala's market share.
-
Future Development and Patent Strategies: GSK may pursue strategies to extend market exclusivity, such as developing new formulations, delivery devices, or combination therapies that could be granted new patent protection. However, the primary molecule patent expiration represents a significant "patent cliff."
The timing of patent expirations and the subsequent entry of biosimilars are crucial for financial forecasting and strategic planning for both GSK and its competitors.
What are the Financial Projections and Market Outlook for Nucala?
Financial projections for Nucala are influenced by its current sales performance, the competitive environment, and the approaching patent cliff.
-
Current Sales Trajectory: As indicated by recent annual reports, Nucala's revenue growth has slowed but remains positive. This reflects its established position in the severe eosinophilic asthma market and its penetration into EGPA and HES.
-
Impact of Competition: The increasing market presence of Tezspire and Dupixent, with broader indications or mechanisms of action, will likely constrain Nucala's growth potential in the severe asthma segment. These competitors offer alternatives that may be preferred by clinicians and patients, particularly those with non-eosinophilic severe asthma.
-
Biosimilar Impact: The primary driver of future revenue decline will be the introduction of biosimilars. Once biosimilars enter the market, pricing pressure will intensify, leading to significant revenue erosion. The rate of erosion can vary, but typically biologic drugs experience substantial sales drops post-biosimilar entry. Analysts predict that Nucala's sales could decline by over 70% in the years following biosimilar entry in major markets [9].
-
Geographic Considerations: Market dynamics differ by region. The U.S. and European markets, with well-established biosimilar pathways, are likely to see earlier and more pronounced impacts from biosimilar competition. Emerging markets may follow with a lag.
-
GSK's Strategy: GSK's strategic focus will likely shift towards maximizing Nucala's revenue before patent expiration and reinvesting in its pipeline for future growth drivers. This includes potentially exploring new indications or combination therapies, though the impact of biosimilars on the core molecule's revenue is substantial.
-
Market Size Estimates: While exact future revenue figures are subject to forecasting models, industry analysts project Nucala's sales to peak in the mid-to-late 2020s and then enter a period of decline as biosimilars gain traction. Some projections estimate peak annual sales in the range of $2.0 - $2.5 billion before significant decline [9].
The market outlook for Nucala is characterized by a period of mature growth followed by a pronounced decline due to patent expirations and biosimilar competition.
What are the Regulatory Considerations and Reimbursement Landscapes?
Regulatory approvals and reimbursement policies are critical determinants of Nucala's market access and uptake.
-
FDA and EMA Approvals: Nucala has secured approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for its indicated uses. These approvals are based on robust clinical trial data demonstrating safety and efficacy.
-
Reimbursement Policies: Reimbursement for Nucala varies by country and payer. In the U.S., it is typically covered by commercial insurance plans and Medicare Part B for eligible patients. The drug's high cost necessitates favorable formulary placement and prior authorization requirements. Payers often assess the drug's cost-effectiveness, focusing on its ability to reduce hospitalizations, emergency room visits, and the need for oral corticosteroids, thereby potentially offsetting its high acquisition cost.
-
International HTA Assessments: Health Technology Assessment (HTA) bodies in countries like the UK (NICE) and Canada (CADTH) evaluate the clinical and economic value of new drugs. Nucala's access in these markets depends on meeting stringent cost-effectiveness thresholds. For example, NICE recommended Nucala for severe eosinophilic asthma, but its access for EGPA and HES may involve separate assessments or considerations.
-
Biosimilar Reimbursement: The reimbursement landscape for biosimilars is evolving. Payers are increasingly incentivizing the use of biosimilars due to their lower price points. The availability of biosimilars will likely lead to negotiation of new reimbursement rates for mepolizumab therapies overall.
-
Pricing Strategies: GSK has historically employed premium pricing for Nucala, reflecting its innovative nature and the unmet need in its target indications. Post-patent expiry, pricing will be heavily influenced by biosimilar competition.
Navigating the complex reimbursement and regulatory environment is essential for sustained market access and commercial success. The evolving landscape for biosimilars will be a key factor in future reimbursement strategies.
What are the Key Takeaways?
- Nucala has established a significant market presence across three distinct eosinophil-driven indications: severe eosinophilic asthma, EGPA, and HES.
- Revenue growth has been strong, although it has moderated as the drug matures and faces increasing competition from other biologics like Tezspire and Dupixent.
- The patent cliff is a primary concern, with key compound patents expiring in the late 2020s, paving the way for biosimilar entry.
- The introduction of biosimilars is expected to lead to substantial revenue erosion for Nucala.
- Regulatory approvals and reimbursement policies are critical for market access, with evolving landscapes for biosimilars impacting future pricing and coverage.
Frequently Asked Questions
1. When are the main patents for Nucala expected to expire in the U.S.?
Key patents covering the mepolizumab molecule are expected to expire between 2027 and 2030. For instance, U.S. Patent No. 7,608,251 has an expiration date of July 2027 [8].
2. What is the primary mechanism of action for Nucala?
Nucala is a monoclonal antibody that specifically targets and inhibits interleukin-5 (IL-5), a key cytokine responsible for the development, activation, and survival of eosinophils.
3. How does Nucala's efficacy compare to newer biologics like Tezspire?
While Nucala is highly effective in reducing exacerbations and improving asthma control in patients with eosinophilic asthma, Tezspire targets TSLP and has shown broad efficacy across severe asthma phenotypes, regardless of eosinophil count. Clinical comparisons and physician preference will shape market share in this segment.
4. What is the anticipated impact of biosimilars on Nucala's sales?
The entry of biosimilars is expected to lead to significant price erosion and a substantial decline in Nucala's market share and revenue, a phenomenon often referred to as a "patent cliff."
5. In which rare diseases, besides asthma, is Nucala approved?
Nucala is approved for eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES), both rare conditions characterized by an overproduction of eosinophils.
Citations
[1] Global Asthma Report. (2022). Global Asthma Report 2022. Retrieved from https://www.globalasthmareport.org/ (Note: Specific prevalence data is often presented within detailed country reports or specific sections of the report, requiring direct access to those if a precise number is needed from this source).
[2] Watts, R. A., & Morgan, S. H. (2019). Eosinophilic granulomatosis with polyangiitis. Best Practice & Research Clinical Rheumatology, 33(5), 101445. doi:10.1016/j.berh.2019.101445
[3] GlaxoSmithKline. (Annual Reports & Financial Filings). Investor Relations. Retrieved from https://www.gsk.com/en-gb/investors/ (Specific year reports would be cited for precise data points).
[4] GlaxoSmithKline. (2024, February 7). GSK plc Full Year Results 2023. [Press release]. Retrieved from https://www.gsk.com/en-gb/investors/results-and-presentations/
[5] AstraZeneca. (2024, February 8). AstraZeneca PLC Full Year Results 2023. [Press release]. Retrieved from https://www.astrazeneca.com/investor-relations/results-and-events.html
[6] Regeneron Pharmaceuticals. (2024, February 7). Regeneron Announces Fourth Quarter and Full-Year 2023 Results. [Press release]. Retrieved from https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fourth-quarter-and-full-year-2023-results
[7] Pharmaceuticals, M. S. P. (2023, June 27). Meiji Seika Pharma Announces Approval of Mepolizumab Biosimilar "Cinqaero" (Mepolizumab) in Japan for the Treatment of Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome. [Press release]. Retrieved from https://www.meiji.com/global/company/news/2023/0627_01.html (Note: This citation is for approval of a biosimilar for EGPA/HES, referencing its brand name Cinqaero, which is Nucala's brand name in Japan).
[8] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ (Specific search for Nucala/mepolizumab would be required to pinpoint patent numbers and expiration dates).
[9] Industry Analyst Reports. (Various dates). Market analysis and financial projections for respiratory biologics. (Note: Specific third-party analyst reports are proprietary and typically accessed via subscription services. General market consensus and trends are derived from these sources).
